Edesa Biotech is trading 10.47% up at $5.91 after investors responded to its August 13 fiscal third-quarter update.
- Reported a $5.4 million quarterly net loss.
- Highlighted activation of Phase 2 EB06 vitiligo study sites and expected Canadian enrollment in the coming weeks.
- No new company press release dated August 17 was listed, suggesting a delayed reaction to the earnings and clinical update.